HC Wainwright Boosts Earnings Outlook for Unicycive Therapeutics

Analysts raise Q1 2026 EPS estimates, see potential for strong long-term growth

Apr. 3, 2026 at 11:08am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial banking equipment, rendered in a high-contrast, cinematic style that conceptually represents the security and infrastructure of the financial system.The complex, industrial machinery that powers the financial system serves as a visual metaphor for the growth and stability of Unicycive Therapeutics' kidney disease treatments.Los Altos Today

Equities research analysts at HC Wainwright have increased their Q1 2026 earnings per share (EPS) estimates for Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a biotechnology company focused on developing novel therapies for kidney diseases. The analysts now anticipate the company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.35).

Why it matters

The improved earnings outlook from HC Wainwright suggests the company's pipeline of kidney disease treatments may be progressing well and could translate to stronger financial performance in the coming years. However, consensus estimates remain mixed, creating some uncertainty around the timing and sustainability of Unicycive's profitability.

The details

In addition to the Q1 2026 estimate increase, HC Wainwright also issued new projections for Unicycive's future earnings, including Q2 2026 EPS of ($0.52), Q3 2026 EPS of ($0.33), and Q4 2026 EPS of ($0.76). The firm also raised its full-year 2026, 2027, 2028, 2029, and 2030 EPS estimates for the company.

  • The updated estimates were issued by HC Wainwright on Tuesday, March 31, 2026.

The players

HC Wainwright

An equities research firm that covers Unicycive Therapeutics.

S. Ramakanth

The HC Wainwright analyst who issued the updated earnings estimates for Unicycive Therapeutics.

Unicycive Therapeutics, Inc.

A biotechnology company developing novel therapies for kidney diseases, based in Los Altos, California.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The improved earnings outlook from HC Wainwright suggests Unicycive's pipeline of kidney disease treatments may be progressing well, though consensus estimates remain mixed, creating some uncertainty around the timing and sustainability of the company's profitability.